Enhanced therapeutic potential of adoptive immunotherapy by in vitro CD28/4-1BB costimulation of tumor-reactive T cells against a poorly immunogenic, major histocompatibility complex class I-negative A9P melanoma

Journal of Immunotherapy

Volumn 23, Issue 4, 2000, Pages 430-437

  Strome, Scott E ^a   Martin, Beth ^a   Flies, Dallas ^a   Tamada, Koji ^a   Chapoval, Andrei I ^a   Sargent, Daniel J ^a   Shu, Suyu ^b   Chen, Lieping ^a  

^a MAYO CLINIC   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

4 1BB; CD28; Costimulation; Malignancy; Tumor Immunity

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPSY; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

4-1BB LIGAND; ANIMALS; ANTIGENS, CD28; CLONE CELLS; CYTOKINES; GENES, MHC CLASS I; IMMUNOTHERAPY, ADOPTIVE; LUNG NEOPLASMS; LYMPH NODES; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; TUMOR CELLS, CULTURED; TUMOR ESCAPE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033938756     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200007000-00006     Document Type: Article

References (26)

1. Shu S, Strome SE, Krauss JC, Plautz GE, Chang AE. Tumor-draining lymph nodes as a source for generating therapeutic immune T cells. In: Chang AE, Shu S, eds. Immunotherapy of Cancer With Sensitized T Lymphocytes. Austin, TX: RG Landes, 1994:1-14.
2. Rosenberg SA, Yannelli JR, Yang JC, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1995;87:319.
3. Chang AE, Aruga A, Cameron MJ, et al. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J Clin Oncol 1997;15:796-807.
4. Plautz GE, Barnett GH, Miller DW, et al. Systemic T cell adoptive immunotherapy of malignant gliomas. J Neurosurg 1998;89:42-51.
5. Linsley PS, Ledbetter JA. The role of the CD28 receptor during T cell response to antigen. Annu Rev Immunol 1993;11:191-212.
6. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996;14:233-58.
7. Chen L, Linsley PS, Hellstrom KE. Costimulation of T cells for tumor immunity. Immunol Today 1993;13:483-6.
8. Harada M, Okamoto T., Omoto K, et al. Specific immunotherapy with tumour-draining lymph node cells cultured with both anti-CD3 and anti-CD28 monoclonal antibodies. Immunology 1996;87: 447-53.
9. Smith CA, Farrah T, Goodwill RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation and death. Cell 1994;76:959-62.
10. Pollok KE, Kim Y-J, Zhou Z, et al. Inducible T cell antigen 4-1BB. Analysis of expression and function. J Immunol 1993;150:771-81.
11. Pollok, KE, Kim SH, Kwon BS. Regulation of 4-1BB expression by cell-cell interactions and the cytokines, interleukin-2 and interleukin-4. Eur J Immunol 1995;25:488-94.
12. Melero I, Johnston JV, Shufford WW, Mittler RS, Chen L. NK1.1 cells express 4-1BB (CDw 137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol 1998;190:167-72.
13. Melero I, Shuford WW, Newby SA, et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997;3:682-5.
14. Melero I, Bach N, Hellstrom KE, Aruffo A, Mittler RS, Chen L. Amplification of tumor immunity by gene transfer of the costimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway. Eur J Immunol 1998;28:1116-21.
15. Shuford WW, Klussman K, Tritchler DD, et al. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med 1997;186:47-55.
16. Hurtado JC, Kim YJ, Kwon BS. Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death. J Immunol 1997;158:2600-9.
17. Takahashi C, Mittler RS, Vella AT. 4-1BB is a bona fide CD8 T cell survival signal. J Immunol 1999;162:5037-40.
18. Saoulli K, Lee SY, Cannons JL, et al. CD28-independent, TRAF2-dependaent costimulation of resting T cells by 4-1BB ligand. J Exp Med 1998;187:1849-62.
19. Guinn BA, DeBenedette MA, Watts TH, Berinstein NL. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine. J Immunol 1999; 162:5003-10.
20. Chen L, Ashe S, Brady, WA, et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992;71:1093-1102.
21. Johnston JV, Malcko AR, Mizuno MT, et al. B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes. J Exp Med 1996;183:791-800.
22. Geiger JD, Wagner PD, Cameron MJ, Shu S, Chang AE. Generation of T-cells reactive to the poorly immunogenic B16-BL6 melanoma with efficacy in the treatment of spontaneous metastases. J Immunother 1993;13:153-65.
23. Peng L, Shu S, Krauss JC. Treatment of subcutaneous tumor with adoptively transferred T cells. Cell Immunol 1997;178:24-32.
24. Chang AE, Shu S. Current status of adoptive immunotherapy of cancer. Crit Rev Oncol Hematol 1996;22:213-28.
25. Kagamu H, Shu S. Purification of L-selectin (low) cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes. J Immunol 1998;160:3444-52.
26. Kjaergaard J. Shu S. Tumor infiltration by adoptively transferred T cells is independent of immunologic specificity but requires down-regulation of L-selectin expression. J Immunol 1999;163:751-9.